ArticleWorld journal of experimental medicine2025
Management of anticoagulation in patients with atrial fibrillation and renal dysfunction: A systematic review.
Article in World journal of experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chemical Synthesis and Biochemical Evaluation of Decasulfated Galloylglucopyranose Heparin Mimetic.Cardiovascular & hematological agents in medicinal chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtrial fibrillation (AF) is a prevalent cardiac arrhythmia associated with significant morbidity and mortality, particularly in patients with concomitant renal dysfunction. Anticoagulation therapy reduces the risk of thromboembolic complications in AF but presents challenges in patients with renal impairment due to altered pharmacokinetics and increased bleeding risk.
aimTo support clinicians in navigating the complexities of anticoagulation in this high-risk population, ensuring optimal outcomes.
methodsThe present review followed PRISMA guidelines. Data extraction was conducted using a standardized template that captured key study characteristics: Population demographics, renal function metrics, anticoagulant dosing strategies, and primary and secondary outcomes. For quality assessment, we employed the Cochrane Risk of Bias 2.0 tool for randomized controlled trials. Observational studies were appraised using the Newcastle-Ottawa Scale.
resultsWe analyze data from 16 studies to provide recommendations on optimal anticoagulation strategies, balancing thrombotic and bleeding risks. Current evidence supports the preferential use of apixaban in moderate chronic kidney disease and cautiously in end-stage renal disease, emphasizing the importance of individualized therapy.
conclusionThe management of anticoagulation in AF patients with renal dysfunction is challenging but critical for reducing stroke risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.